

PC PRODUCTS INDIA LIMITED

(formerly known as Jayavant Industries Limited)

(CIN: L85110TG1996PLC099198)

Registered Office: 4-7-375/A, Television Hotel Lane, Esamia Bazar, Hyderabad-500 027, Telangana; Contact No.: +91 90300 57370; E-Mail ID: pcproductsindia@gmail.com; Website: www.pcproductslimited.com

Open Offer for acquisition of 26,67,300 Equity Shares of ₹10 each representing 26% of the Emerging Voting Capital from the Public Shareholders of PC Products India Limited (hereinafter referred to as the "PC"/"Target Company"), in terms of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto ("SEBI (SAST) Regulations, 2011"/"Regulations") by Dr. Mohammed Aejaz Habeeb ("Acquirer 1"), Dr. Syed Ameer Basha Paspala ("Acquirer 2") and Mr. Kalidindi Krishnam Raju ("Acquirer 3") ("Acquirer 1", "Acquirer 2" & "Acquirer 3" collectively being, the "Acquirers")

This Detailed Public Statement ("DPS") is being issued by Mark Corporate Advisors Private Limited, the Manager to the Offer ("Manager"), for and on behalf of the Acquirers, in compliance with Regulation 13(4) of SEBI (SAST) Regulations pursuant to the Public Announcement ("PA") sent to BSE Limited, Mumbai ("BSE"), Metropolitan Stock Exchange of India Limited Mumbai ("MSEI"), Ahmedabad Stock Exchange Limited, Ahmedabad ("ASE"), and the Target Company on August 24, 2016 and filed with Securities and Exchange Board of India ("SEBI"), Mumbai on August 25, 2016 in terms of Regulation 3(1) and 4 of the SEBI (SAST) Regulations, 2011.

Definitions:

- (a) "Emerging Voting Capital" shall mean the Paid-up Equity Share Capital of 1,02,58,706 Equity Shares of ₹10 (Rupees Ten only) each of the Target Company being the Paid-up Equity Share Capital after the allotment of 48,70,606 Equity Shares.
- (b) "Preferential Allotment"/"Pref Issue" shall mean issue and allotment of 48,70,606 Equity Shares of face value of ₹10 (Rupees Ten only) each at a price of ₹10 (Rupees Ten only) each representing 47.48% of the Emerging Voting Capital of the Target Company against swap of Shares of Krisani Bio Sciences Private Limited ("Krisani") in the ratio of 83:100 i.e. Eighty Three Equity Shares of the Target Company against One Hundred Equity Shares of Krisani.
- (c) "Open Offer/Offer" shall mean the Open Offer made by the Acquirers to the Public Shareholders of the Target Company for the acquisition of 26% of the Emerging Voting Capital in accordance with the Regulations.

I. ACQUIRERS, SELLER, TARGET COMPANY AND OFFER:

A. Information about the Acquirers:

1) Information about Dr. Mohammed Aejaz Habeeb ("Acquirer 1")

1.1. Dr. Mohammed Aejaz Habeeb, s/o Padmashree Late C M Habibullah, aged about 50 years, presently residing at 3-5-1092/A/1, Venkateshwara Colony, Narayanaguda, Hyderabad-500 029, Telangana State, Contact No.: +91 98480 34860, E-Mail: aeajazhabeeb@hotmail.com is a PhD holder in Biotechnology, D.M. (Gastroenterology) and MD. (General Medicine). His Permanent Account Number (PAN) is AAQPH 8503 B.

1.2. Acquirer 1 is working as a Professor and Head of Department of Gastroenterology & Hepatology at Deccan College of Medical Sciences and is also a consultant of Gastroenterology & Hepatology at Apollo Hospital, Hyderabad. He has over 17 years of experience of working as a consultant of Gastroenterology at his clinic at Narayaguda, Hyderabad.

1.3. Acquirer 1 is not part of any group.

As on date, Acquirer 1 does not hold any Equity Share in the Target Company. Further, pursuant to Share Purchase Agreement ("SPA") entered with the Promoter/Seller of the Target Company for 21,00,000 Equity Shares, Acquirer 1 will hold 10,00,000 Equity Shares comprising 9.75% of the Emerging Voting Capital.

1.5. Acquirer 1 has not been prohibited by SEBI from dealing in securities, in terms of directions issued under Section 11B of the SEBI Act or any other regulations made under the SEBI Act.

1.6. The Net Worth of Acquirer 1 is ₹11.67 Crores (Rupees Eleven Crores Sixty Seven Lacs only) as on June 30, 2016 as certified vide certificate dated July 01, 2016 issued by Mr. P. Hanumantha Rao, Partner of M/s V. Rao & Gopi, Chartered Accountants (Membership No. 026990) (FRN: 0031535) having office at Flat No. 001, 3-5-595, Gharonda Paul Apts., 7th Street, Narayaguda, Near Telugu Academy, Hyderabad-500 029, Telangana State, Contact No.: +91 40 2322 8444, Email: vraoandgopi@yahoo.com.

1.7. The major entity promoted/controlled/managed by Acquirer 1 is as under:

Sr. No.	Name of the Partnership Firm	Share of Partnership
1)	Centre for Liver Research and Diagnostics	30.25%

2) Information about Dr. Syed Ameer Basha Paspala ("Acquirer 2")

2.1. Dr. Syed Ameer Basha Paspala, s/o Mr. Syed Mahboob Miah Paspala, aged about 50 years, presently residing at 3-5-167, Flat no. 202, Lakshmi Residence, Venkateshwara Colony, Narayanaguda, Hyderabad-500 029 Contact No.: +91 94949 43848, E-Mail: syedpaspala@gmail.com is a PhD holder in Biotechnology and M.Ch (Neurosurgery). His Permanent Account Number (PAN) is ABLPF 1002 B.

2.2. Acquirer 2 is working as a Professor and Head of Department of Neurosurgery at Deccan College of Medical Sciences and is also a consultant of Neurosurgeon at Care Hospital, Hyderabad. He has over 16 years of experience of working as a consultant of Neurosurgeon.

2.3. Acquirer 2 is not part of any group.

2.4. As on date, Acquirer 2 does not hold any Equity Share in the Target Company. Further, pursuant to Share Purchase Agreement ("SPA") entered with the Promoter/Seller of the Target Company for 21,00,000 Equity Shares, Acquirer 2 will hold 10,00,000 Equity Shares comprising 9.75% of the Emerging Voting Capital.

2.5. Acquirer 2 has not been prohibited by SEBI from dealing in securities, in terms of directions issued under Section 11B of the SEBI Act or any other regulations made under the SEBI Act.

2.6. The Net Worth of Acquirer 2 is ₹13.95 Crores (Rupees Thirteen Crores Ninety Four Lacs only) as on March 31, 2016 as certified vide certificate dated July 07, 2016 issued by Mr. G. Sambasiva Rao, Partner of M/s G Sambasiva Rao & Co., Chartered Accountants (Membership No. 023047) (FRN: 003537S) having office at H. No. 8-3-682/1/B, Navodaya Colony, Srinagar Colony Post, Hyderabad-500 073, Telangana State, Telefax No.: +91 40 2374 2422, Email: gsrao_co@rediffmail.com.

2.7. The major entity promoted/controlled/managed by Acquirer 2 is as under:

Sr. No.	Name of the Partnership Firm	Share of Partnership
1)	Centre for Liver Research and Diagnostics	30.25%

3) Information about Mr. Kalidindi Krishnam Raju ("Acquirer 3")

3.1. Mr. Kalidindi Krishnam Raju, s/o Mr. K V Subba Raju, aged about 57 years, presently residing at 8-2-293/8/2/J/11, Plot No. 12, Road No. 82, Jubilee Hills, Hyderabad-500 033, Telangana State, Contact No.: +91 98494 33333, E-Mail: kalidindir@gmail.com is a Chartered Accountant from The Institute of Chartered Accountants of India. His Permanent Account Number (PAN) is ADOPK 7164 N.

3.2. Acquirer 3 has experience of over 25 years in the field of Finance, Accounts, and Administration.

3.3. Acquirer 3 is not part of any group.

As on date, Acquirer 3 does not hold any Equity Share in the Target Company. Further, pursuant to Share Purchase Agreement ("SPA") entered with the Promoter/Seller of the Target Company for 21,00,000 Equity Shares. Out of which Acquirer 3 will hold 1,00,000 Equity Shares comprising 0.975% of the Emerging Voting Capital.

3.5. Acquirer 3 has not been prohibited by SEBI from dealing in securities, in terms of directions issued under Section 11B of the SEBI Act or any other regulations made under the SEBI Act.

3.6. The Net Worth of Acquirer 3 is ₹21.68 Crores (Rupees Twenty One Crores and Sixty Eight Lacs only) as on June 30, 2016 as certified vide certificate dated July 28, 216 issued by Mr. Mahidhar S. G., Partner of M/s Vsweswara Rao & Associates, Chartered Accountants (Membership No. 216463) (FRN: 005774S) having office at "SR" 8-2-686/DB/22/1, Road No. 12, Banjara Hills, Hyderabad-500 034, Telangana State, Contact No.: +91 40 23548003, Email: svrrao@gmail.com.

3.7. The major entity promoted/controlled/managed by Acquirer 3 is as under:

Sr. No.	Name of the Entities	% of total Equity Shares held/Share of Partnership
1)	Centre for Liver Research and Diagnostics (Partnership Firm)	8.00%
2)	Krisani Bio Sciences Private Limited	27.04%
3)	Innovision Life Sciences Private Limited	67.50%
4)	Krisani Innovation Private Limited	1.10%
5)	Krisani Wealth Management Private Limited	4.55%
6)	Krisani Knowledge Resources Private Limited	10.00%
7)	Krisani Electronics and Electricals Private Limited	1.10%

4) The Acquirers are Business Associates and came together to control the Target Company jointly.

5) The Acquirers did not acquire Equity Shares of the Target Company during twelve (12) months period prior to Public Announcement made to the Shareholders of the Target Company.

6) There is an informal arrangement between the Acquirers with regard to the acquisition of Shares through Open Offer. Neither the Acquirers nor any of the entities with which they are associated, are in Securities related business and registered with SEBI as a Market Intermediary.

8) None of the entities promoted or controlled by the Acquirers as mentioned in point no. 1.7, 2.7 & 3.7 above are either participating or acting in Concert with the Open Offer.

9) As on the date of this DPS, the Acquirers does not have any interest in the Target Company, except for acquisition of 21,00,000 Equity Shares through SPA and 48,70,606 Equity Shares proposed to be allotted through Preferential Allotment. Further, there are no Directors representing the Acquirers on the Board of the Target Company.

10) There are no persons Acting in Concert in relation to the Offer within the meaning of 2(1)(q)(1) of SEBI (SAST) Regulations, 2011.

B. Information about the Seller:

1) Pursuant to the Share Purchase Agreement ("SPA") entered on August 24, 2016, the Acquirers have agreed to acquire 21,00,000 Equity Shares of Face Value of ₹10 (Rupees Ten only) each at a price of ₹4.00 (Rupees Four only) per share representing 20.47% of the Emerging Voting Capital from the following Shareholder of the Target Company (hereinafter referred as "Seller"/"Selling Shareholder"):-

Sr. No.	Name & PAN	Part of Promoter Group (Yes/No)	Details of Shares/Voting Rights held by the Selling Shareholder					
			Pre Transaction			Post Transaction		
			No. of shares	% vis a vis total Share Capital	% vis a vis Emerging Voting Capital	No. of Shares	% vis a vis total Share Capital	% vis a vis Emerging Voting Capital
1)	Mr. Arun Kumar Bhangadia PAN: AAOPB 7586 N Address: 8-2-684/1/2, Flat No. G-6, Rock Levelz Apartment, Road No. 12, Banjara Hills, Hyderabad-500 034	Yes	29,26,800	54.32%	28.52%	8,26,800	15.35%	8.06%
TOTAL			29,26,800	54.32%	28.52%	8,26,800	15.35%	8.06%

2) The above Shares agreed to be acquired through SPA have been transferred to Demat Escrow Account namely "PC-Open Offer-Demat Escrow Account", opened with B N Rathi Securities Limited, whose operating authority rests with the Manager to the Offer and the same will be transferred to the Acquirer's account upon completion of the Open Offer formalities.

3) The Seller has not been prohibited by SEBI from dealing in securities, in terms of directions issued under Section 11B of the SEBI Act, 1992, as amended or under any other regulation made under the SEBI Act, 1992.

4) The Seller acquired 28,55,800 Equity Shares in the FY 2014-2015 representing 53% of the then Equity Share Capital/Voting Capital of the Target Company in accordance with SEBI (SAST) Regulations, 2011.

C. Information about the Target Company-PC Products India Limited (formerly known as Jayavant Industries Limited) (hereinafter referred to as "PC"/"Target Company"):-

1) The Target Company, bearing CIN L85110TG1996PLC099198 was incorporated on January 25, 1996 in the name of Jayavant Industries Limited in Bangalore, Karnataka pursuant to the provisions of the Companies Act, 1956 and certificate for Commencement of Business was obtained on February 01, 1996. The name of the Company was changed from 'Jayavant Industries Limited' to 'PC Products India Limited' vide new Certificate of Incorporation dated October 01, 2014.

2) The Registered Office of the Target Company shifted to Telangana State w.e.f April 30, 2015 and is presently situated at 4-7-375/A, Television Hotel Lane, Esamia Bazar, Hyderabad-500 027.

3) The Target Company is engaged mainly in the trading of all kinds of Papers. The Target Company recently diversified into the business of sale of Wholesale Drugs and has obtained Drug License from Drugs Control Administration, Hyderabad, Government of Telangana on July 28, 2016.

4) The Equity Shares of the Target Company are listed on BSE Limited, Mumbai ("BSE") w.e.f. August 11, 2015, Metropolitan Stock Exchange of India Limited, Mumbai ("MSEI") w.e.f. November 20, 2014 and Ahmedabad Stock Exchange Limited, Ahmedabad ("ASE").

5) The Authorized Share Capital of the Target Company is ₹6,00,00,000 comprising 60,00,000 Equity shares of ₹10 each. The paid-up Share Capital of the Target Company is ₹5,38,81,000, comprising of 53,88,100 Equity Shares of ₹10 each. However, the Company vide its Board Meeting held on August 24, 2016 has approved the Increase in Authorized Share Capital from ₹6,00,00,000 (Rupees Six Crores only) comprising of 60,00,000 Equity Shares of ₹10 (Rupees Ten only) each to ₹13,00,00,000 (Rupees Thirteen Crores only) comprising of 1,30,00,000 Equity Shares of ₹10 (Rupees Ten only) each.

6) The Equity Shares of the Target Company are listed on BSE Limited, Mumbai ("BSE"), with Scrip Code as 539267, Metropolitan Stock Exchange of India Limited, Mumbai ("MSEI"), with Scrip Code as PCPROD and Ahmedabad Stock Exchange Limited, Ahmedabad ("ASE"), with Scrip Code as 28101. The Equity Shares of the Target Company are infrequently traded within the meaning of explanation provided in Regulation 2(i) of the SEBI (SAST) Regulations, 2011. The ISIN of the Target Company is INE579N01018.

7) As on date, the Target Company is fully compliant with the listing requirements and there has not been any non-listing of Equity Shares on any of the Stock Exchanges.

8) The present Promoter acquired Shares and took over the control of the Target Company in the year 2014-2015 pursuant to SEBI (SAST) Regulations, 2011 and thereafter he has been complying with Chapter II of SEBI (SAST) Regulations, 1997 and Chapter V of the SEBI (SAST) Regulations, 2011.

9) The key financial information of the Target Company are based on the Audited Financial Statements for the Financial Year ended March 31, 2016, March 31, 2015 and March 31, 2014 and Certified Un-Audited Financials, as certified by the Statutory Auditor, for the three months period ended June 30, 2016 subject to limited review by the statutory auditors.

Particulars	Period Ended June 30, 2016	FY 2015-16	FY 2014-15	FY 2013-2014
	(Un-audited)	(Audited)	(Audited)	(Audited)
Total Revenue	32.45	374.25	406.68	7.87
Net Income (Profit/Loss for the year)	(4.22)	1.44	2.72	6.69
EPS (In ₹ per share)	Negative	0.03	0.05	0.12
Net Worth/Shareholders' Fund	376.49	380.71	379.27	376.54

(Source: Annual Accounts for the financial years ended March 31, 2016, March 31, 2015, March 31, 2014 and Certified Un-Audited financials for the period ended June 30, 2016 subject to limited review by the statutory auditors).

10) The Board of Directors of the Target Company consists of Mr. Devendra Kumar Rathi, Whole Time Director (DIN: 0666601) Mr. Arun Kumar Bhangadia, Promoter/Non-Executive Director (DIN: 00021024), Mr. Praveen Bellam, Independent Director (DIN:06968003), Mr. Bonthu Pardhasara, Independent Director (DIN: 07337785) and Ms. Nishita Kalantri, Independent Director (DIN: 07444639).

11) The Company Secretary and the Compliance Officer of the Target Company is Ms. Pooja Jain.

D. Details of the Offer:

1) The Acquirers are making this Open Offer to acquire upto 26,67,300 Equity Shares of ₹10 each, representing 26% of the Emerging Voting Capital of the Target Company at a price of ₹10 (Rupees Ten only) per Equity Share ("Offer Price") aggregating to ₹2,66,73,000 (Rupees Two Crores Sixty Six Lacs and Seventy Three Thousand only), payable in cash, subject to the terms and conditions set out in the Public Announcement ("PA"), this Detailed Public Statement ("DPS") and the Letter of Offer ("LoF") which will be sent to the Public Shareholders of the Target Company.

2) All the owners of the equity shares of the Target Company, registered or unregistered, except the Acquirer, Proposed Allottees under Preferential Allotment and the Selling Shareholder are eligible to participate in the Offer in terms of Regulation 7(b) of SEBI (SAST) Regulations, 2011.

3) The payment of consideration will be made to all the Public Shareholders, who have validly tendered their shares in acceptance of the Offer, within ten (10) working days from the expiry of the Tendering Period.

4) As on date, to the best of knowledge and belief of the Acquirers, there are no other statutory approvals required to acquire the equity shares tendered pursuant to this Offer, except for in-Principle approval of the Stock Exchange(s) for listing of the Equity Shares proposed to be issued under Preferential Issue and approval of the Shareholders of the Target Company by way of Postal Ballot, the result of which will be declared on or before October 03, 2016. If any other statutory approvals are required or become applicable at a later date before the completion of the Offer, the Offer would be subject to the receipt of such other statutory approvals. The Acquirers will not proceed with the Offer in the event such statutory approvals are refused in terms of Regulation 23 of the SEBI (SAST) Regulations, 2011.

5) This Offer is not conditional upon any minimum level of acceptance by the Equity Shareholders of the Target Company in terms of Regulation 19(1) of the SEBI (SAST) Regulations, 2011.

6) This is not a competing offer in terms of Regulation 20 of SEBI (SAST) Regulations, 2011.

7) The Equity Shares of the Target Company which will be acquired by the Acquirers are fully paid up, free from all liens, charges and encumbrances and together with the rights attached thereto, including all rights to dividend, bonus and rights offer declared thereof.

8) As on date, there are no instruments pending for conversion into Equity Shares.

9) The Manager to the Offer i.e. Mark Corporate Advisors Private Limited does not hold any Equity Shares in the Target Company as on the date of appointment to act as Manager to the Offer. They declare and undertake that they shall not deal in the Equity Shares of the Target Company during the period commencing from the date of their appointment as Manager to the Offer till the expiry of 15 days from the date on which the payment of consideration to the shareholders who have accepted the Open Offer is made, or the date on which the Open Offer is withdrawn as the case may be.

E. The Acquirers does not have any plans to alienate any significant assets of the Target Company whether by way of sale, lease, encumbrance or otherwise for a period of two (2) years except in the ordinary course of business. The Target Company's future policy for disposal of its assets, if any, within two (2) years from the completion of Offer will be decided by its Board of Directors, subject to the applicable provisions of the law and subject to the approval of the shareholders through Special Resolution passed by way of Postal Ballot in terms of Regulation 25(2) of SEBI (SAST) Regulations, 2011.

F. As per Regulation 38 of SEBI (LODR), Regulations, 2015 read with Rule 19A of the Securities Contract (Regulation) Rules, 1957, as amended ("SCRR"), the Target Company is required to maintain at least 25% Public Shareholding, on continuous basis for listing. Pursuant to completion of this Offer, assuming full acceptance, the public shareholding in the Target Company will fall below the minimum public shareholding requirement as per SCRR as amended and the Listing Agreement. However, the Acquirers undertake to take necessary steps to facilitate Compliances of the Target Company with the relevant provisions of the Listing agreement within the time period mentioned therein.

II. BACKGROUND TO THE OFFER:

1) The Acquirers have entered into a Share Purchase Agreement ("SPA") on August 24, 2016 with the existing Promoter (the "Selling Shareholder"/"Seller") to acquire 21,00,000 Equity Shares of ₹10 each representing 20.47% of the Emerging Voting Capital of the Target Company. Further, on August 24, 2016 the Board of Directors of the Target Company inter-alia approved a Preferential Allotment of 48,70,606 Equity Shares of Face Value of ₹10 each representing 47.48% of the Emerging Voting Capital of the Target Company against swap of Shares of Krisani Bio Sciences Private Limited ("Krisani") in the ratio of 83:100 i.e. Eighty Three Equity Shares of the Target Company against One Hundred Equity Shares of Krisani. Out of which 25,82,130 Equity Shares shall be allotted to one of the Acquirers i.e. Acquirer 3 and balance 22,88,476 Equity Shares to the relatives of Acquirer 3.

2) Pursuant to SPA and Preferential Allotment, the Acquirers are making an Offer in terms of Regulation 3(1) and 4 of SEBI (SAST) Regulations, 2011 to acquire upto 26,67,300 Equity Shares of ₹10 each, representing 26% of the Emerging Voting Capital of the Target Company ("Offer Size") at a price of ₹10 (Rupees Ten only) per Equity Share ("Offer Price"), payable in cash, subject to the terms and conditions set out in the PA, this Detailed Public Statement and the Letter of Offer that will be sent to the public shareholders of the Target Company.

3) The Offer Price is payable in cash, in accordance with Regulation 9(1) of SEBI (SAST) Regulations.

4) At present, the Acquirers do not have any plans to make major changes to the existing line of business of the Target Company except in the ordinary course of business. The Acquirers may expand the existing business of the Target Company and may diversify into Bio Pharma sector with the prior approval of the Shareholders. The Acquirers may reorganize the present Capital structure of the Company and also further strengthen the Board.

5) The Object of the acquisition is substantial acquisition of Shares/Voting Rights accompanied by controlling the Management of the Target Company.

III. SHAREHOLDING AND ACQUISITION DETAILS:

The current and proposed Equity Shareholding of the Acquirers in the Target Company and the details of their acquisitions are as follows:

Particulars	Shareholding as on PA date		Shares agreed to be acquired through SPA & Preferential Allotment		Shares acquired between PA date and the DPS date		Shares proposed to be acquired in the Offer (assuming full acceptance)		Post Offer shareholding as on 10 th working day after closing of Tendering Period	
	No. of Shares	%*	No. of Shares	%*	No. of Shares	%*	No. of Shares ^A	% ^A	No. of Shares	%*
Acquirer 1	Nil	N.A.	10,00,000	9.75%	Nil	N.A.				
Acquirer 2	Nil	N.A.	10,00,000	9.75%	Nil	N.A.	26,67,300	26.00%	96,37,906	93.95%
Acquirer 3	Nil	N.A.	49,70,606 ¹	48.45%	Nil	N.A.				
TOTAL	Nil	N.A.	69,70,606	67.95%	Nil	N.A.	26,67,300	26.00%	96,37,906	93.95%

^AAssuming full acceptance in the Open Offer.

^{*}The above percentages are calculated on the basis of Emerging Voting Capital.

¹Out of 49,70,606 Equity Shares, 48,70,606 Equity Shares to be allotted through Preferential Allotment (25,82,130 Equity Shares to Acquirer 3 and balance 22,88,476 Equity Shares to the relatives of Acquirer 3).

IV. OFFER PRICE:

1) The Equity Shares of the Target Company are presently listed on BSE Ltd, Mumbai ("BSE") having a scrip code as 539267, Metropolitan Stock Exchange of India Limited, Mumbai ("MSEI"), with Scrip Code as PCPROD and Ahmedabad Stock Exchange Limited, Ahmedabad ("ASE"), with Scrip Code as 28101.

2) The annualized trading turnover of the Equity Shares of the Target Company during Twelve (12) calendar months preceding the month of PA (August 2015 to July 2016) on the Stock Exchange on which the Equity Shares of the Target Company are listed is given below:

Name of the Stock Exchange	Total Number of shares traded during the preceding 12 calendar months prior to the month of PA	Total No. of Equity Shares listed	Annualized trading turnover (as % of total number of listed shares)
BSE Ltd	3,68,396	53,88,100	6.84%
MSEI	Nil	53,88,100	Nil
ASE	Nil	53,88,100	Nil

(Source: www.bseindia.com)

3) Based on the above, the Equity Shares of the Target Company are infrequently traded during twelve (12) calendar months preceding the calendar month in which PA is made within the meaning of explanation provided in Regulation 2(i) of the SEBI (SAST) Regulations, 2011.

4) The Offer Price of ₹10 (Rupees Ten Only) is justified in terms of Regulation 8(2) of the SEBI (SAST) Regulations on the basis of the following:

Sr. No.	Particulars	Amount (In. ₹)
a)	Negotiated Price as per SPA	: 4.00
b)	The volume-weighted average price paid or payable for acquisition whether by the Acquirer, during 52 weeks preceding the date of PA	: N.A.
c)	The highest price paid or payable for any acquisition, whether by the Acquirer, during 26 weeks preceding the date of the PA	: N.A.
d)	The volume-weighted average market price of Equity shares of the Target Company for a period of sixty (60) trading days immediately preceding the date of PA as traded on BSE, being the Stock Exchange where the maximum volume of trading in the shares of the Target Company are recorded during such period.	: 7.76
e)	Other Financial Parameters as at:	31.03.2016 (Audited)
i)	Return on Net Worth	: 0.38
ii)	Book Value Per Share	: 7.07
iii)	Earnings Per Share	: 0.03